Pericapsular Nerve Group Block Added to Intra-articular Corticosteroid Injection in the Treatment of Hip Pain

NCT07427238 | Completed

• 1 other identifier: Hip OA pain
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

Osteoarthritis (OA) is a leading cause of chronic musculoskeletal pain and functional disability worldwide, affecting an increasing number of people. Despite various conservative and interventional treatment approaches, pain, the most important clinical problem in the disease, is suboptimally controlled. Hip osteoarthritis is a chronic condition characterized by progressive degeneration of the joint cartilage and inflammation of the synovial membrane. The incidence of symptomatic hip OA is estimated to be approximately 25%, and its prevalence is increasing due to the aging of the global population and the rise in obesity (1). Conservative methods such as oral medications and physical therapy modalities are available for its management. However, in some patients, pain persists despite these conservative treatment methods, and ongoing pain significantly impairs patients' daily living activities. There are some interventional treatment methods used in these patients, and the most commonly used methods are intra-articular corticosteroid (CS) and local anesthetic (LA) injections and, in some patients, a pericapsular nerve (PENG) block administered in addition to these injections.

Conditions

Hip Pain Chronic; Osteoarthritis, Hip

Keywords

osteoarthritis; hip pain; intraarthicular injection; pericapsular nerve group block

Outcome Measures

Primary Outcomes (1)

• Numerical rating scale (NRS)

  NRS is a scale that can be used measuring pain. Scores range from 0 (no pain) to 10 (the worst pain)

  Change from baseline to 1st, 3rd and 12th weeks after treatment

Secondary Outcomes (1)

• The Western Ontario McMaster University Osteoarthritis (WOMAC) Index

  Change from baseline to 1st, 3rd and 12th weeks after treatment

Study Arms (2)

Intra-articular injection

During hip intra-articular injection, the patient is placed supine, and following sterile cleaning and draping, the ultrasound probe is placed transversely in the inguinal region. After visualizing the femoral head and femoral artery, vein, and nerve, local anesthesia with 1% lidocaine is applied to the needle entry site after visualizing the femoral head and neck junction and the joint cartilage. Then, a 22-gauge, 100-mm needle is advanced toward the joint capsule, targeting the junction of the femoral neck and femoral head. Once the target area is reached, 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the joint.

Procedure: Intra-articular injection

Intra-articular injection + PENG block

After intra-articularf injection; additionally, during the PENG block, the patient is placed supine, and following sterile cleaning and draping, the anterior inferior iliac spine (AIIS) and iliopubic eminence (IPE) are visualized using a convex ultrasound probe. The target for the PENG block is the musculo-fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After applying local anesthesia to the skin with 1% lidocaine, a 22-gauge, 100 mm needle is inserted and 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the target area. Patients are monitored for possible complications.

Procedure: Intra-articular injection + PENG blok

Interventions

Intra-articular injection + PENG blok PROCEDURE

In addition to intra-articular injection, the anterior inferior iliac spine and iliopubic eminence are visualized under ultrasound guidance. A 22-gauge, 100 mm needle is inserted into the musculo-fascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly, and 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the target area.

Intra-articular injection + PENG block

Intra-articular injection PROCEDURE

Under US guidance, following visualization of the femoral head and neck junction and the articular cartilage, a 22-gauge, 100-mm needle is advanced toward the joint capsule, targeting the junction of the femoral neck and femoral head. Once the target area is reached, 2 ml of dexamethasone and 2 ml of 0.025% bupivacaine are injected into the joint.

Intra-articular injection

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients with hip pain lasting longer than 6 months due to hip osteoarthritis that has not improved with conservative methods and who have therefore undergone ultrasound-guided intra-articular steroid + local anesthetic injection and/or PENG block.

You may qualify if:

• Patients with hip pain due to hip osteoarthritis who have undergone hip intra-articular steroid + local anesthetic injection and/or PENG block under ultrasound guidance for this reason
• Persistence of pain for more than 6 months
• Failure of pain treatment with conservative methods

You may not qualify if:

• Those with inflammatory rheumatic joint disease (rheumatoid arthritis, gout, pseudogout, metabolic joint diseases),
• History of major trauma, hip surgery
• Cognitive dysfunction, history of psychiatric illness
• Hepatic or renal insufficiency
• Local or systemic infection
• Coagulopathy

Sponsors & Collaborators

• Saglik Bilimleri Universitesi: lead

Study Sites (1)

Ezgi Can

Ankara, 06010, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Osteoarthritis, Hip; Osteoarthritis

Interventions

Injections, Intra-Articular

Condition Hierarchy (Ancestors)

Arthritis; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases

Intervention Hierarchy (Ancestors)

Injections; Drug Administration Routes; Drug Therapy; Therapeutics

Study Officials

• Alp Eren Çelenlioğlu, MD

  Gulhane School of Medicine

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 16, 2026
• First Posted: February 23, 2026
• Study Start: February 1, 2025
• Primary Completion: September 1, 2025
• Study Completion: September 2, 2025
• Last Updated: February 23, 2026

Record last verified: 2026-02

Locations

TU (1)